Ilja Demuth

Dr. Ilja Demuth

Department of Endocrinology and Metabolic Diseases (including Division of Lipid Metabolism), Biology of Aging Working Group, Charité – Universitätsmedizin Berlin, 13353 Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2016 in Nature
Verified
Journal Article
Open access
PDF file
AOAysu Okbay
Aysu Okbay
JBJonathan P. Beauchamp
Jonathan P. Beauchamp
MFMark Alan Fontana
Mark Alan Fontana
JLJames J. Lee
James J. Lee
TPTune H. Pers
Tune H. Pers
DBDaniel J. Benjamin
Daniel J. Benjamin
Educational attainment is strongly influenced by social and other environmental factors, but genetic factors are estimated to account for at least 20% of the variation across individuals1. Here we report the results of a genome-wide association study (GWAS) for educational attainment that extends our earlier discovery sample1,2 of 101,069 individuals to 293,723 individuals, and a replication study in an independent sample of 111,349 individuals from the UK Biobank. We identify 74 genome-wide significant loci associated with the number of years of schooling completed. Single-nucleotide polymorphisms associated with educational attainment are disproportionately found in genomic regions regulating gene expression in the fetal brain. Candidate genes are preferentially expressed in neural tissue, especially during the prenatal period, and enriched for biological pathways involved in neural development. Our findings demonstrate that, even for a behavioural phenotype that is mostly environmentally determined, a well-powered GWAS identifies replicable associated genetic variants that suggest biologically relevant pathways. Because educational attainment is measured in large numbers of individuals, it will continue to be useful as a proxy phenotype in efforts to characterize the genetic influences of related phenotypes, including cognition and neuropsychiatric diseases.

1 February 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Open access
ASAmand Schmidt
Amand Schmidt
DSDaniel I Swerdlow
Daniel I Swerdlow
MHMichael V Holmes
Michael V Holmes
RPRiyaz S Patel
Riyaz S Patel
ZFZammy Fairhurst-Hunter
Zammy Fairhurst-Hunter
NSNaveed Sattar
Naveed Sattar
Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk. In this mendelian randomisation study, we used data from cohort studies, randomised controlled trials, case control studies, and genetic consortia to estimate associations of PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores. Data were available for more than 550 000 individuals and 51 623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0·09 mmol/L, 95% CI 0·02 to 0·15), bodyweight (1·03 kg, 0·24 to 1·82), waist-to-hip ratio (0·006, 0·003 to 0·010), and an odds ratio for type diabetes of 1·29 (1·11 to 1·50). Based on the collected data, we did not identify associations with HbA1c (0·03%, -0·01 to 0·08), fasting insulin (0·00%, -0·06 to 0·07), and BMI (0·11 kg/m2, -0·09 to 0·30). PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins. British Heart Foundation, and University College London Hospitals NHS Foundation Trust (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre.

1 February 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYingchang Lu
Yingchang Lu
FDFelix R. Day
Felix R. Day
SGStefan Gustafsson
Stefan Gustafsson
MBMartin L. Buchkovich
Martin L. Buchkovich
JNJianbo Na
Jianbo Na
RLRuth J. F. Loos
Ruth J. F. Loos
To increase our understanding of the genetic basis of adiposity and its links to cardiometabolic disease risk, we conducted a genome-wide association meta-analysis of body fat percentage (BF%) in up to 100,716 individuals. Twelve loci reached genome-wide significance (P<5 × 10−8), of which eight were previously associated with increased overall adiposity (BMI, BF%) and four (in or near COBLL1/GRB14, IGF2BP1, PLA2G6, CRTC1) were novel associations with BF%. Seven loci showed a larger effect on BF% than on BMI, suggestive of a primary association with adiposity, while five loci showed larger effects on BMI than on BF%, suggesting association with both fat and lean mass. In particular, the loci more strongly associated with BF% showed distinct cross-phenotype association signatures with a range of cardiometabolic traits revealing new insights in the link between adiposity and disease risk.

1 November 1998 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JWJohan P. de Winter
Johan P. de Winter
QWQuinten Waisfisz
Quinten Waisfisz
MRMartin A. Rooimans
Martin A. Rooimans
CBCarola G.M. van Berkel
Carola G.M. van Berkel
LBLucine Bosnoyan-Collins
Lucine Bosnoyan-Collins
HJHans Joenje
Hans Joenje

14 March 2013 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
LBLars Bertram
Lars Bertram
ABAnke Böckenhoff
Anke Böckenhoff
IDIlja Demuth
Ilja Demuth
SDSandra Düzel
Sandra Düzel
RERahel Eckardt
Rahel Eckardt
ESElisabeth Steinhagen-Thiessen
Elisabeth Steinhagen-Thiessen
Similar to other industrialized countries, Germany's population is ageing. Whereas some people enjoy good physical and cognitive health into old age, others suffer from a multitude of age-related disorders and impairments which reduce life expectancy and affect quality of life. To identify and characterize the factors associated with ‘healthy’ vs. ‘unhealthy’ ageing, we have launched the Berlin Aging Study II (BASE-II), a multidisciplinary and multi-institutional project that ascertains a large number of ageing-related variables from a wide range of different functional domains. Phenotypic assessments include factors related to geriatrics and internal medicine, immunology, genetics, psychology, sociology and economics. Baseline recruitment of the BASE-II cohort was recently completed and has led to the sampling of 1600 older adults (age range 60–80 years), as well as 600 younger adults (20–35 years) serving as the basic population for in-depth analyses. BASE-II data are linked to the German Socio-Economic Panel Study (SOEP), a long-running panel survey representative of the German population, to estimate sample selectivity. A major goal of BASE-II is to facilitate collaboration with other research groups by freely sharing relevant phenotypic and genotypic data with qualified outside investigators.

27 February 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MWMarco Witkowski
Marco Witkowski
INIna Nemet
Ina Nemet
HAHassan Alamri
Hassan Alamri
JWJennifer Wilcox
Jennifer Wilcox
NGNilaksh Gupta
Nilaksh Gupta
SHStanley L. Hazen
Stanley L. Hazen